A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects with Early Alzheimer's Disease

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500691-59-00

Acronym

M22-721

Enrollment

Registered

2023-07-28

Start date

Unknown

Completion date

2024-06-27

Last updated

2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease (AD)

Brief summary

The primary efficacy endpoint for Stage B is change from Baseline in brain amyloid plaque deposition (amyloid centiloid value) at Week 24 as measured by amyloid PET scan.

Interventions

DRUGPlacebo

DRUGMK-6240

DRUGABBV-916

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary efficacy endpoint for Stage B is change from Baseline in brain amyloid plaque deposition (amyloid centiloid value) at Week 24 as measured by amyloid PET scan.	—

Countries

Italy, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026